A Phase 3 interventional study of Fluvoxamine and Placebo in Post-COVID, POST-Covid 19 and Post-COVID Conditions, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands — 6 open to participants now, 6 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Netherlands.
Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, this one is one of 3 that started in 2026, is one of 3 in phase 3, and was the 15th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →6 of the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands are open now. Recruiting first, the newest first:
Michele van Vugt · Sites in Netherlands
Ages 18–65
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18–65
Amsterdam UMC, location VUmc · Sites in Netherlands
Ages 18+
Janneke van de Wijgert · Sites in Netherlands
Ages 18+
Erasmus Medical Center · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 4
First in 2020; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 75 across the 8 interventional studies, 256 across the 7 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 10 most frequent:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 533 studies on the registry; 182 are open to participants now.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) has 3 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Post-Acute COVID-19 Syndrome with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07298005Michele van VugtSonlicromanol in Post-COVID | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fatigue, cognitive problems, post-exertional malaise (PEM) and postural orthostatic tachycardia syndrome (POTS) are common and debilitating symptoms after COVID-19. The pathophysiology of post-COVID is not well understood and there is no established biomedical treatment. Treatment options for post-COVID are thus much needed.
A promising candidate intervention is fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), that may reduce post-COVID symptoms because of its regulatory effect on the (neuro) immune system, the hypothalamic-pituitary-adrenal (HPA) axis and the tryptophan system. The investigators will randomize 160 participants to either fluvoxamine or placebo for 12 weeks.
The investigators will use advanced functional neuroimaging techniques during cognitive challenge (optional substudy) and plasma biomarkers (inflammatory markers, cortisol, serotonin, IDO-2 activity), to facilitate identifying potential mechanistic pathways of post -COVID treatment.
In this randomized placebo-controlled trial, the investigators will study the effectiveness of fluvoxamine in reducing fatigue severity (primary outcome), cognitive problems, PEM and POTS after 12 weeks of treatment in 160 post-COVID patients.
Moreover, the investigators will study treatment-emergent changes in plasma biomarkers, including blood-based neuro)inflammatory markers, cortisol, serotonin, aryl hydrocarbon receptor -indoleamine 2,3-dioxygenase-2 (IDO-2) and kynurenine pathway (KP) metabolites for potential mechanistic pathways of post-COVID treatment.
Numerous studies have indicated involvement of brain dysfunction in post COVID, which also relate to the degree of symptom severity (e.g. fatigue / cognitive problems). In an optional neuro-imaging sub-study, the investigators will use functional neuroimaging techniques with and without cognitive challenge to gain a better understanding of the brain functioning and structure in long COVID during fluvoxamine treatment versus placebo.
Objectives:
Optional Neuro-imaging sub-study:
-To determine which changes occur on functional brain imaging, brain metabolites and neuroinflammation during cognitive challenge and to determine if this brain response to cognitive challenge changes after fluvoxamine treatment versus placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluvoxamine.
Drug: Fluvoxamine
Placebo
Drug: Placebo
Subject are randomized in a double-blind manner (1:1 ratio) between fluvoxamine and placebo. During the first week subjects will receive a low dose daily dose of fluvoxamine of 25 mg or placebo. In the second week, subjects will receive a daily dose of 50 mg or placebo. From week 3 onwards, the fluvoxamine or placebo dose is increased by daily 50 mg every 6 days in a blinded manner but will not be further increased if participants are unwilling to accept a dose increase. For doses higher than 100 mg per day, dosing is done twice daily. The dose is increased to a maximum of 200 mg per day (i.e. 100 mg bid). The minimal daily dose is 50 mg.
Subject are randomized in a double-blind manner (1:1 ratio) between fluvoxamine and placebo. During the first week subjects will receive a low dose daily dose of fluvoxamine of 25 mg or placebo. In the second week, subjects will receive a daily dose of 50 mg or placebo. From week 3 onwards, the fluvoxamine or placebo dose is increased by daily 50 mg every 6 days in a blinded manner but will not be further increased if participants are unwilling to accept a dose increase. For doses higher than 100 mg per day, dosing is done twice daily. The dose is increased to a maximum of 200 mg per day (i.e. 100 mg bid). The minimal daily dose is 50 mg.
Fatigue severity
Fatigue scale of the Checklist Individual Strength (CIS-20R). This scale has a minimum score of 8 and a maximum score of 56. High score indicate worse outcome.
Time frame: week 12
Fatigue severity
Dutch-Flemish Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue short form 8a. A higher scores indicates worse outcome.
Time frame: week 4, 8, 12
Cognitive functioning
Dutch-Flemish Patient-Reported Outcome Measurement Information System (PROMIS) cognitive function 8a. Higher scores indicate better functioning.
Time frame: week 4, 8, 12
Cognitive functioning
Concentration score on the Checklist Individual Strength (CIS-20R). This scale has a minimum score of 5 and a maximum score of 35. A higher score indicates worse outcome.
Time frame: week 4, 8, 12
PEM
DePaul Symptom Questionnaire (DSQ) Post Exertional Malaise (PEM). Higher scores indicate worse outcome.
Time frame: week 4, 8, 12
POTS (National Aeronautics and Space Administration (NASA) lean test
NASA lean test
Time frame: week 12
POTS
DePaul Symptom Questionnaire (DSQ) Postural Orthostatic Tachycardia Syndrome (POTS). Higher scores indicate worse outcome.
Time frame: week 4, 8, 12
Health-related Quality of Life
Dutch-Flemish Patient-Reported Outcome Measurement Information System (PROMIS) Profile-29. Higher scores indicate better outcome.
Time frame: week 4, 8, 12
Disability
Bell disability score. The minimum score is 0. The maximum score is 100. Higher scores indicate better outcome.
Time frame: week 4, 8, 12
Side effects
Antidepressant Side Effect Checklist-21 (ASEC-21). Higher scores indicate worse outcome.
Time frame: week 12
Side effects
Frequency, Intensity, Burden of Side Effects Rating scale (FIBSER scale). Higher scores indicate worse outcome.
Time frame: week 12
Brain Perfusion (optional MRI substudy)
Arterial Spin Labeling
Time frame: week 12
Brain functioning and connectivity (optional MRI substudy)
During resting-state and cognitive effort (challenging N-back (3-back vs. 0-back) on functional MRI
Time frame: week 12
Brain metabolites and neuroinflammation (optional MRI substudy)
Magnetic Resonance Spectroscopy
Time frame: week 12
Biomarkers
(neuro) inflammation markers, corticoid receptor activity and cortisol, serotonin, IDO-2/ KP metabolites
Time frame: week 12
Plan to share: Yes — Sharing will be in accordance with Dutch privacy laws and regulations.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluvoxamine
Post-Acute COVID-19 Syndrome →
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) →